Global Stem Cell Umbilical Cord Blood Industrial and Market studies 2016-2019
Albany, New York, Jan 11,2017
"Global
Stem Cell Umbilical Cord Blood Market 2015-2019"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
UCB
is the blood that remains in the placenta and the attached umbilical
cord after childbirth. UCB contains stem cells that are unique,
smart, and are capable of treating several life-threatening diseases.
They are used in the treatment of hematopoietic and genetic
disorders. The placental blood can produce 10 times more quantity of
stem cells compared to the umbilical cord, which can in turn be used
for the treatment of an adult patient. The cord blood that is
collected during the childbirth is stored and cryopreserved. The
storage of the cord blood can be done at private cord blood banks or
public cord blood banks. This preserved blood can be used for the
transplantation, and treatment of diseases at the later stages of
life.
*
Technavio's analysts forecast the global stem cell UCB market to
grow at a CAGR of 30.36% over the period 2014-2019.
–
Covered
in this Report
The
report covers the present scenario and the growth prospects of the
global stem cell UCB market for the period 2015-2019. To calculate
the market size, the report considers revenue generated from the
banking and utilization of UCB stem cells for the treatment of
various disorders, such as cancers, blood disorders, metabolic
disorders, immune diseases, and others.
Technavio's
report, Global Stem Cell UCB Market 2015-2019, has been prepared
based on an in-depth market analysis with inputs from industry
experts. The report covers the Americas, APAC, and EMEA; it also
covers the landscape of the global stem cell UCB market and its
growth prospects in the coming years. The report includes a
discussion of the key vendors operating in this market.
–
Key
Regions
Americas
APAC
EMEA
–
Key
Vendors
Caladrius
Biosciences
Celgene
Mesoblast
Pluristem
Therapeutics
–
Other
Prominent Vendors
Athersys
CHA
Bio & Diostech
Cytori
Therapeutics
Nuo
Therapeutics
Ocata
Therapeutics
Opexa
Therapeutics
Osiris
Therapeutics
Teva
Pharmaceuticals
United
Therapeutics
–
Key
Market Driver
Effective
Treatment of Life-threatening Diseases
For
a full, detailed list, view our report
–
Key
Market Challenge
Stringent
Regulations
For
a full, detailed list, view our report
–
Key
Market Trend
Growing
Public Awareness
For
a full, detailed list, view our report
–
Key
Questions Answered in this Report
What
will the market size be in 2019 and what will the growth rate be?
What
are the key market trends?
What
is driving this market?
What
are the challenges to market growth?
Who
are the key vendors in this market space?
What
are the market opportunities and threats faced by the key vendors?
What
are the strengths and weaknesses of the key vendors?
Comments
Post a Comment